Plus Therapeutics, Inc. (PSTV)
Automate Your Wheel Strategy on PSTV
With Tiblio's Option Bot, you can configure your own wheel strategy including PSTV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PSTV
- Rev/Share 0.1727
- Book/Share -3.1916
- PB -0.0577
- Debt/Equity -0.0017
- CurrentRatio 1.0293
- ROIC -9.715
- MktCap 6029762.0
- FreeCF/Share -1.7371
- PFCF -0.4686
- PE -0.0503
- Debt/Assets 0.0033
- DivYield 0
- ROE 2.3898
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PSTV | D. Boral Capital | -- | Buy | -- | $9 | March 17, 2025 |
News
Plus (PSTV) Upgraded to Buy: Here's Why
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.
Read More
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference.
Read More
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company's new proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the marketing application (NDA) is submitted.
Read More
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral
HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. "This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies," said Marc H.
Read More
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
Read More
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H.
Read More
About Plus Therapeutics, Inc. (PSTV)
- IPO Date 2001-07-11
- Website https://www.plustherapeutics.com
- Industry Biotechnology
- CEO Dr. Marc H. Hedrick M.B.A., M.D.
- Employees 21